Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Pharmacy Regulation Compounding topic
No spam. Unsubscribe anytime.
Senate committee approves rewrite of pharmacy rules but removes three compounding distribution lines after stakeholder concerns
Summary
The Idaho Senate Health and Welfare Committee approved a comprehensive rewrite of the Idaho State Board of Pharmacy rule chapter while striking three subparts that governed distribution/labeling of compounded drug products after stakeholder concern and debate about federal guidance and patient access.
The Senate Health and Welfare Committee on an oral vote approved pending changes to the Idaho State Board of Pharmacy rule chapter (IDAPA 24.36.01) but removed three lines of text that governed the distribution and labeling of compounded drug products.
The rule rewrite — part of a broader zero-based review (ZBR) of pharmacy regulations — was presented by Nikki Chopsky, bureau chief for health professions at the Division of Occupational and Professional Licenses and executive officer for the Idaho State Board of Pharmacy. Chopsky told the committee the board reviewed more than 35 changes to the chapter and had engaged pharmacy stakeholders, national associations and the Idaho Medical Association in multiple public meetings and hearings.
"The board did a comprehensive review and made more than 35 changes to this chapter," Chopsky said during her presentation, describing reorganized sections on licensure, practice standards, compounding and prescription drug monitoring.
Why it matters: the removed language concerned how compounded products distributed by pharmacies or prescribers are labeled — a technical but consequential detail that affects how out‑of‑state compounders, in‑state compounders and distributors operate and how patients obtain some compounded medications. Stakeholders queried whether Idaho’s language was more restrictive than federal guidance and whether sticking to the state text could limit access or raise costs.
During committee discussion, Senator Lenny used an analogy to describe the tension between state and federal approaches: "It seems like Idaho is the teacher saying, I know the principal said we can have snacks on campus, but we're gonna enforce this no snack rule." Chopsky replied to that analogy, "Yes. You nailed it," and said the board was cautious about incorporating draft federal guidance into state rule because several states that moved quickly to adopt evolving federal guidance later faced litigation.
Action and vote: the committee considered two related motions. First, members had earlier voted to "take no action" on a temporary rule docket (24-3601-2401) so that temporary language would expire. Later, the committee considered the pending ZBR chapter (24-3601-2402). Senator Lenny offered a substitute to approve the pending chapter while striking subsections identified in the book as 214(E)(i) and 214(E)(ii). The substitute motion passed on a roll call: 7 yeas, 2 nays.
Chopsky said the board will continue outreach with stakeholders and monitor federal developments. She noted recent federal draft guidance is non‑binding and the board did not want to adopt unsettled guidance by reference. The board also said there are in‑state legal pathways for some compounded products and that the ZBR process allows future review if federal rules are finalized.
The committee approved the pending chapter with the specified deletions, and Chopsky said the board will continue to work with industry and other stakeholders on workable solutions for compounding and distribution.
The committee also recorded that the temporary rule docket would be allowed to expire after a majority voted to take no action on it earlier in the meeting.
Looking ahead: Chopsky told senators she expects continued stakeholder engagement and possible future rule changes if federal guidance evolves or litigation affects national practice.
